Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826797 | 0.78 | BIRC2 (0.38) | PLA2G10PLA2G5BIRC2XIAPALDH1A1 | |
| SCHEMBL16854473 | 0.78 | BIRC2 (0.38) | PLA2G10PLA2G5BIRC2XIAPALDH1A1 | |
| SCHEMBL2906920 | 0.76 | BIRC2 (0.37) | PLA2G10PLA2G5BIRC2MAPT | |
| SCHEMBL4960304 | 0.74 | BIRC2 (0.35) | PLA2G10PLA2G5BIRC2MAPT | |
| SCHEMBL17153062 | 0.74 | BIRC2 (0.55) | PLA2G10PLA2G5BIRC2XIAP | |
| SCHEMBL17155371 | 0.71 | SIGMAR1 (0.40) | PLA2G10PLA2G5ALDH1A1 | |
| SCHEMBL17153059 | 0.70 | BIRC2 (0.38) | PLA2G10PLA2G5BIRC2XIAP | |
| SCHEMBL17153080 | 0.69 | BIRC2 (0.37) | PLA2G10PLA2G5BIRC2XIAPMAPT | |
| SCHEMBL649131 | 0.66 | SIGMAR1 (0.50) | PLA2G10PLA2G5MEN1ALDH1A1MAPT | |
| SCHEMBL4134315 | 0.66 | SIGMAR1 (0.50) | PLA2G10PLA2G5MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | PLA2G10 2046/4885PLA2G5 2401/4885BIRC2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.